An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.

  title={An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.},
  author={Frances Rena Bahjat and Polly R. Pine and Andrea J Reitsma and Gail Cassafer and Muhammad Baluom and Sunny K Grillo and Betty Y. Chang and Fei Fei Zhao and Donald G. Payan and Elliott B. Grossbard and David I. Daikh},
  journal={Arthritis and rheumatism},
  volume={58 5},
OBJECTIVE To assess whether R788, an orally bioavailable small molecule inhibitor of spleen tyrosine kinase (Syk)-dependent signaling, could modulate disease in lupus-prone (NZB x NZW)F1 (NZB/NZW) mice via inhibition of Fc receptor (FcR) and B cell receptor signaling. METHODS R788 was administered to NZB/NZW mice before and after disease onset. Proteinuria, blood urea nitrogen levels, and autoantibody titers were examined periodically, and overall survival and renal pathologic features were… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 66 extracted citations

Tyrosine kinases in inflammatory dermatologic disease.

Journal of the American Academy of Dermatology • 2011
View 6 Excerpts
Highly Influenced

Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2017
View 1 Excerpt

Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2017


Publications referenced by this paper.
Showing 1-10 of 52 references

CD8 T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression

RP Singh, A La Cava, M Wong, F Ebling, BH. Hahn
J Immunol • 2007
View 1 Excerpt

R935788: a phase II, single center, open label, efficacy and safety, ascending dose, pilot study for the treatment of adult immune thrombocytopenic purpura (ITP) [abstract

JB Bussel, AM Schindler, EB. Grossbard
Blood • 2007

Syk kinase inhibition by R406 inhibits BCR mediated B cell proliferation and interferes with BCR signal transduction in primary tumor samples [abstract

JP Sharman, J Irish, O Hatton, O Martinez, R. Levy
Blood 2007;110:802 • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…